Baxter International Inc (BAX)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 4,975,000 | 5,066,000 | 5,105,000 | 4,587,000 | 4,761,000 |
Revenue | US$ in thousands | 14,847,000 | 15,164,000 | 12,731,000 | 23,192,000 | 22,616,000 |
Gross profit margin | 33.51% | 33.41% | 40.10% | 19.78% | 21.05% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $4,975,000K ÷ $14,847,000K
= 33.51%
The gross profit margin of Baxter International Inc. has shown a declining trend over the past five years, decreasing from 41.90% in 2019 to 33.59% in 2023. This indicates that the company's profitability from sales after deducting the cost of goods sold has been on a downward trajectory. The declining trend could be attributed to various factors such as increased production costs, pricing pressures, or changes in product mix. It is important for the company to closely monitor and manage its cost structure to improve its gross profit margin and overall profitability in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Baxter International Inc
BAX
33.51%
3M Company
MMM
43.46%
Artivion Inc
AORT
69.22%
Becton Dickinson and Company
BDX
5.65%
Boston Scientific Corp
BSX
70.81%
DexCom Inc
DXCM
63.52%
Embecta Corp
EMBC
67.44%
Glaukos Corp
GKOS
79.40%
Globus Medical
GMED
65.05%
Haemonetics Corporation
HAE
26.65%
ICU Medical Inc
ICUI
32.75%